Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
2020 Life Science Innovation Northwest - Hall of Fame
Share |

Life Science Washington created the Washington Life Science Hall of Fame in 2016 to honor industry leaders and pioneers in the field. The Washington State Life Science Hall of Fame recognizes individuals who have made exceptional contributions to the life science field over the course of their career and lifetime, changing the course of scientific history and impacting our community at large. The award recognizes contributions from across our private and public industries including biopharmaceuticals, biotechnology, medical device, digital health/health IT, global health, research institutions, investment, and public leadership.




Colleen Delaney, MD, MSc

Founder and Chief Scientific Officer, Executive Vice President of Research and Development, Nohla Therapeutics

Dr. Colleen Delaney is the scientific founder and Chief Scientific Officer of Nohla Therapeutics, a Seattle biotech focused on the radical idea of offering patients with cancer and other critical diseases "off-the-shelf" cell therapies that provide universal patient benefit. The therapies hold the potential to be more effective and more accessible than traditional stem cell transplants. In 2006, as a member of the Fred Hutch clinical research division, Dr. Delaney established and became the director of the new Cord Blood Transplant Program at the Fred Hutch/Seattle Cancer Care Alliance. Since then, the cord blood program has grown to be one of the leading programs in the country, and serves as coordinator for multicenter clinical trials.

Dr. Delaney’s work has led to clinical studies aimed at offering patients better infection-fighting support while they undergo cancer treatments. It also resulted in the spin out of the technology and start of Nohla Therapeutics in December 2015. In 2018, the FDA granted Nohla’s lead product, Dilanubicel, fast-track orphan status for its potential to benefit patients. The European Medicines Agency has awarded it a similar designation.

Dr. Delaney is a graduate of Oxford University and Harvard Medical School and is the recipient of numerous awards, including the prestigious Damon Runyon Foundation Clinical Investigator Award. For her contributions and leadership to nurturing STEM education and helping future women scientists, Dr. Delaney last year was honored by American Women in Science.

Ron Howell

Chief Executive Officer, Washington Research Foundation

Ron Howell is the Chief Executive Officer of Washington Research Foundation (WRF), one of the most successful technology transfer, grant making and investment organizations in the nation. Under Mr. Howell’s leadership, WRF has provided grants and licensing disbursements of more than $535 million to Washington-based nonprofit research institutions. WRF Capital, the Foundation’s venture investment arm, was formed in 1994 to invest in local early-stage STEM companies. WRF Capital’s investment managers have backed more than 98 companies, with more than 60 exits and an active portfolio of 37 companies today. Returns support the Foundation’s grant making programs.

Mr. Howell has served on a number of boards at the University of Washington, Washington State University, Fred Hutchinson Cancer Research Center and The W Fund. He holds a bachelor of science in biochemistry from Washington State University. Prior to joining WRF, Mr. Howell was in medical sales and operations.

Steve Reed, PhD

Distinguished Investigator, IDRI

Steve Reed founded IDRI in 1993 and has served in a variety of leadership roles since that time. Currently, Steve serves as a Distinguished Investigator.

His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health, and has served as a member of diagnostic and vaccine steering committees of the World Health Organization. In 1994, he co-founded Corixa Corporation (which was later sold to GlaxoSmithKline, GSK) where he served as Chief Scientific Officer until leaving in 2004. In 2008 Steve co-founded Immune Design Corp. where he served as CEO until 2011.

Steve has more than 250 original publications, 40 book chapters and reviews, and 105 issued patents on diagnostics, vaccines, and therapeutics of infectious diseases and cancer.


Alan Frazier

Founder and Chairman, Frazier Healthcare Partners

Dr. Frazier has led Frazier Healthcare Partners in raising nine institutional funds and managing nearly $3.0 billion in assets. During his 25 years as the company’s Managing Partner and Chairman, he’s worked with entrepreneurs to build many leading healthcare companies, among them Array (NASDAQ: ARRY), Tularik (acquired by Amgen), Rigel (NASDAQ: RIGL), CV Therapeutics (acquired by Gilead), VIVUS (NASDAQ: VVUS), Corixa (acquired by GSK), and Cadence (acquired by Mallinckrodt). He currently sits on the boards of Abode Healthcare and Orthotic Holdings.

Before founding Frazier, he was integrally involved in growing several successful healthcare companies into national prominence, including Immunex Corporation. Later, he served as the Senior Financial Advisor and CFO of Affymax and its spin-out Affymetrix. Before Immunex, Mr. Frazier was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young & Company (now, Ernst & Young).

Denise A. Galloway, PhD

Director, Pathogen-Associated Malignancies Integrated Research Center, Fred Hutchinson Cancer Research Center, and Research Professor, Departments of Microbiology, Pathology & Global Health, University of Washington

Dr. Galloway’s Lab studies the mechanisms by which human papillomaviruses contribute to cancer, with an emphasis on types most likely to progress to cervical cancer. Galloway and colleagues work to understand the natural history of genital HPV infections and why only a small subset of women infected with high-risk HPVs develop cancer. Her work has been instrumental in developing the HPV vaccines in use today.

As Director of the Fred Hutch Pathogen-Associated Malignancies Integrated Research Center, Galloway brings together Hutch experts in infectious diseases, host-pathogen interactions, cancer biology, immunology, global oncology and immunotherapy to understand, treat and prevent the cancers linked to infectious agents. She is an elected member of the American Academy of Microbiology and the American Association for the Advancement of Science, a recipient of a Fred Hutch 40th Anniversary Endowed Chair and serves on the National Cancer Institute (NCI) Board of Scientific Counselors.

Leland Hartwell, PhD

Professor, Center for Sustainable Health, Arizona State University and Former President and Director Emeritus, Fred Hutchinson Cancer Research Center

Dr. Hartwell’s pioneering research has had a major influence on our understanding of cancer and the therapeutic strategies used to treat diseases caused by uncontrolled cell growth. He was awarded the 2001 Nobel Prize in Physiology or Medicine. By identifying "checkpoint" genes that determine whether a cell is dividing normally, Hartwell provided important clues to cancer, which arises from abnormal, uncontrolled cell growth.

From 1997-2010 Hartwell was President and Director of the Fred Hutchinson Cancer Research Center. During that period The Hutch completed its expansion and consolidation to the South Lake Union campus and formed the Seattle Cancer Care Alliance in partnership with the University of Washington and Seattle Children’s Hospital. He joined the faculty of the Arizona State University in 2010 where he has appointments in the Schools of Education, Biomedical Engineering, and Sustainability.

Christopher H. Porter, PhD

Commercialization Consultant, Life Science Washington Institute and CEO, Medical Genesis

For the past seven years, Dr. Porter has served as a Commercialization Consultant for Life Science Washington and Life Science Washington Institute, advising over 400 life science startups in this role. He was instrumental in setting up the Washington Innovation Mentoring (WIN) program and continues to be an active mentor. He has also been an avid volunteer for WINGS, a non-profit angel network that facilitates seed and early stage investments for medical technology companies in the Pacific Northwest.

Dr. Porter is also CEO of Medical Genesis, a consulting firm and medical device incubator. Throughout his career, he has been a CEO and/or board member of numerous public and private companies. He founded, invented products for, and contributed heavily to the success of numerous life science companies. He has been influential in introducing over 30 medical products and holds 48 US patents.


Former Washington Governor, Christine Gregoire


Gregoire is well-known throughout our state for her career in public service. The first woman elected to attorney general in the state of Washington, she served in that post for three terms before being elected governor. As governor, she worked with the Washington State Legislature to create the Life Sciences Discovery Fund as an investment in the future of the life sciences sector in Washington. Since leaving office, Gregoire has stayed involved, chairing the Import-Export Bank Advisory Committee and serving as chair of the Fred Hutchinson Cancer Research Center Board of Trustees. Currently, Gregoire serves as CEO of Challenge Seattle, which aims to make our region more vibrant and globally competitive.

Lee Huntsman, PhD

UW President Emeritus, Professor Emeritus

After more than two decades of distinguished service in academic leadership, Huntsman was named President Emeritus by the University of Washington Board of Regents in 2004. From 2005 to 2012, he served as the first executive director of the Life Sciences Discovery Fund Authority, a public-private partnership intended to advance life sciences research in the state. Currently, Huntsman is exploring ways the UW and Washington state might become more agile and successful in the reinvention of health care. Huntsman has been elected Fellow of the American Institute of Medical and Biological Engineering, the Biomedical Engineering Society and the American Association for the Advancement of Science.

Bruce Montgomery, MD

Chief Executive Officer, Avalyn Pharma

Dr. Montgomery has extensive pharmaceutical company experience in drug development, operations and financing. Currently the CEO of Genoa Pharmaceuticals, he was previously the CEO of Cardeas Pharma. He also founded and served as CEO of Corus Pharma, Inc. Montgomery has raised hundreds of millions of dollars in venture or public financings and authored 28 US patents. He was co-inventor of aerosolized pentamidine, the second AIDS drug approved by the FDA, and has received numerous honors. In 2015, he was elected to the Washington State Academy of Sciences. He is currently on the boards of Alder, Xencor, Vicis and M3Bio and served for a decade as a trustee of the Life Sciences Discovery Fund. Montgomery is a board-certified internist and pulmonologist.

Stewart Parker

Principal, Parker BioConsulting

Stewart Parker is the Principal of Parker BioConsulting. Previously, she served as the CEO of the Infectious Disease Research Institute (IDRI). She also served as the Commercialization Consultant for the Washington Biotechnology and Biomedical Association (now Life Science Washington), assisting emerging companies in their business planning, strategy and fundraising. An entrepreneur, Parker is the founder and former president and CEO of Targeted Genetics Corporation, a Seattle biotechnology company. Previously, she was vice president of corporate development at Immunex Corporation as well as president, CEO and board member of Receptech Corporation. She is the recipient of numerous awards and currently sits on several for-profit and nonprofit boards of directors, including the board of WINGS, the nonprofit angel network for medical technology companies in the Pacific Northwest. .


Donald W. Baker

Revolutionized Medical Ultrasound through Doppler Technology

Donald W. Baker was one of the student engineers recruited to develop instruments that Rober Rushmere could not buy, nor had the knowledge, background or training to create. This development lead to a family of instruments directed at the non-invasive analysis of the human cardiovascular system. Among many instruments was the Continuous Wave Ultrasonic Doppler Flow Detector, The Pulsed Ultrasonic Doppler Flow Meter, and ultimately, the Color flow combined imaging and blood flow detection system, which is now a worldwide standard configuration of all comprehensive ultrasonic diagnostic instruments. The task went well beyond simply creating, testing and developing instruments; it meant eventually teaching the world of medicine the values and role of blood flow information and anatomy in medical diagnosis. This led to a worldwide program of teaching, seminars, and workshops in many countries and with many cultures. Baker identified himself as an "Electrical Engineer come Bioengineer" with experience in Bio-Electronics Instrumentation research and development, with more than 20 years of experience and exposure to research in Vascular Disease, Vascular surgery, Adult and Pediatric Cardiology, and Ob-GYN, amongst other specialties. The knowledge and experience Baker and his colleagues gained was transferred from the University in 1973 into the formation of Advanced Technology Laboratories, Bellevue. The company was transformed in the process into a multidisciplinary medical engineering company, and is now one of the world’s largest Ultrasound companies under Philips imaging.

Karl William Edmark, MD

Founder, Physio-Control

Karl William Edmark, MD, was a cardiovascular surgeon and lifelong inventor who was committed to improving outcomes for patients undergoing cardiac surgery. His best-known contribution was to defibrillation science. In the early to mid 1950s, defibrillators used alternating current (AC), which was unreliable and used a high-voltage wave form. Edmark developed a defibrillator that utilized direct current (DC), which provided lower-energy shocks with less trauma to patients and was more reliable and effective in terminating ventricular fibrillation. Edmark's invention, known as the Edmark Pulse Defibrillator, was first used to save the life of a 12-year-old girl in Seattle in 1961. Edmark founded Physio-Control in 1955. He later hired W. Hunter Simpson to direct the company's growth, while he continued to develop products to benefit patients with cardiac conditions. Edmark's company went on to revolutionize emergency medical care by introducing the first portable defibrillator/monitor that enabled paramedics to provide defibrillation in the field, before transporting the patient to the hospital. This improvement was an important factor in the advent of Seattle's Medic One, a pioneering emergency medical service founded in 1970.

Steven Gillis, PhD

Managing Director, ARCH Venture Partners

Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. GlaxoSmithKline acquired Corixa Corporation in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. He currently serves as a director or Chairman of multiple private and public biotechnology companies in the United States.

Leroy Hood, MD, PhD

President and Co-Founder, Institute for Systems Biology, Senior Vice President and Chief Science Officer, Providence Health & Services

Dr. Hood was involved in the development of five instruments critical for contemporary biology: automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood’s direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15. In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology, the first of its kind. He has pioneered systems medicine the years since ISB’s founding. Hood has made many seminal discoveries in the fields of immunology, neurobiology and biotechnology and, most recently, has been a leader in the development of systems biology, its applications to cancer, neurodegenerative disease, and the linkage of systems biology to personalized medicine. Hood is now pioneering new approaches to P4 medicine—predictive, preventive, personalized and participatory, and most recently, has embarked on creating a P4 pilot project on 100,000 well individuals, that is transforming healthcare. In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale.

E. Donnall Thomas, MD and Dorothy "Dottie" Thomas

Nobel Laureate, Fred Hutchinson Cancer Research Center

Known as the father and mother of bone marrow transplantation, Dr. E. Donnall Thomas and his wife, Dorothy (affectionately known as “Dottie”), forever changed the world of cancer treatment. The Thomases formed the core of a team that proved bone marrow transplantation could indeed cure leukemia and other blood cancers, lifesaving work that spanned several decades and gave rise to the field of immunotherapy. Thomas’ breakthroughs in the field earned him the 1990 Nobel Prize (he was quick to share credit with his wife who did everything from assist in the lab to research, write and edit his grants and papers) but his most powerful legacy is measured in the number of lives saved every year. Today, more than 1 million transplants have been performed around the world, transforming a collection of deadly cancers into highly treatable diseases. When Thomas first came to Seattle in 1963, his team at the University of Washington sought to do what many were convinced would never work: use radiation and chemotherapy to destroy a patient’s diseased bone marrow, then replace it with healthy donated marrow. The goal was to establish a new, cancer-free blood and immune system. Thomas’ early success convinced Seattle surgeon Dr. William Hutchinson to build a permanent home for cancer research, a home that eventually became the Fred Hutchinson Cancer Research Center. Thomas joined Fred Hutch in 1974.

more Calendar

2/25/2020 » 2/27/2020
Workshop: Ensuring supply chain flexibility and viability for biologics

Featured Member
Biotech Primer Inc.Biotech Primer develops and delivers customized training to the Life Sciences community

Membership Management Software Powered by YourMembership  ::  Legal